Trial
NCT03306420
First-in-Human Study of MS201408-0005A as Single Agent and in Combinations
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Merck KGaA, Darmstadt, Germany
Condition
Metastatic or Locally Advanced Unresectable Solid Tumors
Intervention
M4112
Why stopped
The study was terminated early due to lackluster pharmacodynamic data that showed no significant reduction of plasma kynurenine at steady state of M4112.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-02-06